PixarBio, Inc. (OTCMKTS: PXRB) is a biotechnology company focused on precise genome engineering and nucleotide-level gene editing. The company’s proprietary GeneWiz platform combines base editing, gene silencing and targeted gene insertion technologies to develop novel therapeutic candidates. PixarBio’s R&D efforts encompass applications in oncology, rare genetic disorders and metabolic diseases, leveraging its patent‐protected toolset to address unmet medical needs.
In addition to its internal pipeline, PixarBio offers contract research and development services to global pharmaceutical and biotechnology clients. These services include custom cell line generation, microbial strain engineering, protein expression and characterization, and process development. By providing end‐to‐end support from design to delivery, the company aims to accelerate preclinical timelines and de‐risk early‐stage programs for its partners.
Founded in 2018 and headquartered in Salt Lake City, Utah, PixarBio has expanded its footprint with R&D facilities in the United Kingdom and Mexico, supporting a growing international client base. The company has established collaborative relationships with academic institutions and industry players to advance its platform and broaden the scope of its therapeutic research. Historical milestones include securing key patents for base editing and completing its first pilot manufacturing runs.
PixarBio’s executive team brings together seasoned professionals in molecular biology, pharmaceutical development and financial management. The leadership roster includes individuals with decades of experience in genome editing, commercial strategy and corporate governance, guiding the company through strategic partnerships and regulatory pathways. This depth of expertise positions PixarBio to pursue both in-house programs and service‐based revenue streams as it continues to scale.
AI Generated. May Contain Errors.
